Determination of the maximal carcinoma/normal skin ratio after HpD or m-THPC administration in Hairless mice (SKH-1) by fluorescence spectroscopy

Anti-Cancer Drugs

Volumn 11, Issue 2, 2000, Pages 85-91

  Bossu, Edwige ^a,b   Padilla Ybarra, Juan José ^b,c   Notter, Dominique ^a,b   Vigneron, Claude ^a,b   Guillemin, François ^b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b U de Rech en T P du C A V   (France)

^c CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

Author keywords

Carcinoma normal skin ratio; Fluorescence spectroscopy; Skin carcinomas; Three stage carcinogenesis

Indexed keywords

HEMATOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; TETRA(HYDROXYPHENYL)CHLORINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; FLUORESCENCE SPECTROSCOPY; MOUSE; NONHUMAN; NUDE MOUSE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN CARCINOMA;

ANIMALS; CARCINOMA; DISEASE MODELS, ANIMAL; FEMALE; HEMATOPORPHYRINS; INJECTIONS, INTRAPERITONEAL; MESOPORPHYRINS; MICE; MICE, INBRED HRS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PREDICTIVE VALUE OF TESTS; SKIN; SKIN NEOPLASMS; SPECTROMETRY, FLUORESCENCE; TISSUE DISTRIBUTION;

EID: 0034113036     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200002000-00004     Document Type: Article

References (31)

1. Yuspa SH, Dlugosz AA. Cutaneous carcinogenesis: Natural and experimental. In: Goldsmith LA, ed. Physiology, Biochemistry and Molecular Biology of the Skin, 2nd Edn. Oxford: Oxford University Press 1991; 1365-402.
2. Agarwald R, Athar M, Elmets CA, et al. Photodynamic therapy of chemically- and ultraviolet B radiation-induced murine skin papillomas by chloroaluminium phtalocyanine tetrasulfonate. Photochem Photobiol 1992; 56: 43-50.
3. Biel MA. Photodynamic therapy as an adjuvant intraoperative treatment of recurrent head and neck carcinomas. Arch Otolaryngo Head Neck Surg 1996; 122: 1261-5.
4. Ma L, Moan J, Berg K. Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: A comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 1994; 57: 883-8.
5. Savary JF, Monnier P, Fontolliet C, et al. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra(hydroxyphenyl)chlorin. Arch Otolaryngol Head Neck Surg 1997; 123: 162-8.
6. Guillemin F, A'Amar O, Rezzoug H, et al. Optical instrumentation suitable for a real time dosimetry during photodynamic therapy. Prog Biomed Optics (Proc Optoelectronic Research and Technologies) 1995; 2627: 92-9.
7. Bossu E, A'Amar O, Parache RM, et al. Determination of the maximal tumor/normal skin ratio after HpD or m-THPC administration in hairless mouse (SKH-1) by fluorescence spectroscopy - A non-invasive method. Anti-Cancer Drugs 1997; 8: 67-72.
8. Braichotte D, Savary JF, Glanzmann T, et al. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of esophagus using fluorescence spectroscopy. Lasers Surg Med 1996; 19: 340-6.
9. Whelpton R, Michael-Titus AT, Basra SS, et al. Distribution of temoporfin, a new photosensitizer for the photodynamic therapy of cancer, in a murine tumor model. Photochem Photobiol 1995; 61: 397-401.
10. Peng Q, Moan J, Ma LW, et al. Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphyrine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res 1995; 55: 2620-6.
11. Heyerdahl H, Wang I, Liu DI., et al. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett 1997; 112: 225-31.
12. Orenstein A, Kostenich G, Malik Z. The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumors. Cancer Lett 1997; 120: 229-34.
13. Azzi V, Notter D, Merlin JL, et al. Composition and spectral characteristics, cytotoxicity and quantum yield of singlet oxygen formation of haematoporphyrin derivative preparation. In: Spinelli P, Dalfante M, Marchesini R, eds. Photodynamic Therapy and Biomedical Lasers. Amsterdam: Excerpta Medica 1992: 715-9.
14. 10-II. Photodermatol Photoimmunol Photomed 1991; 8: 169-75.
15. Wang Q, Altermatt HJ, Ris HB, et al. Determination of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin in tissues by high performance liquid chromatography. Biomed Chromatogr 1993; 7: 155-7.
16. A'Amar O, Lignon D, Ménard O, et al. Autofluorescence spectroscopy of normal and malignant tissues: Both in vivo and ex-vivo measurements in the upper aero-digestive tract and lung tissues. SPIE: Advances in Laser and Light Spectroscopy to Diagnose Cancers and Other Diseases III: Optical Biopsy 1996; 2679: 42-50.
17. Glanzmann T, Theumann JF, Braichotte D, et al. Pharmacokinetics of meso-(tetrahydroxyphenyl)chlorin (m-THPC) studied by fluorescence spectroscopy on early cancer of the cheek pouch mucosa of golden syrian hamsters. Prog Biomed Optics (Proc Optical Biopsy and Fluorescence Spectroscopy and Imaging) 1994; 2324: 89-96.
18. Ortéga N, Sordello S, Plouët J. Vascularisation tumorale: Physiopathologie et perspectives thérapeutiques. Bull Cancer 1997; 84: 391-5.
19. Peng Q, Evensen JF, Rimington C, et al. A comparison of different photosensitizing dyes with respect to uptake by C3H tumours and tissues of mice. Cancer Lett 1987; 36: 1-10.
20. Elmer EB, Wood WC, Cohen AM, et al. Effect of route of administration on the selectivity of haematoporphyrin derivative for tumour tissue. J Surg Oncol 1987; 34: 113-9.
21. Amano T, Prout GR, Lin C. Intratumour injection as a more effective means of porphyrin administration for photodynamic therapy. J Urol 1988; 139: 392-5.
22. Morlet L, Vonarx V, Foultier MT, et al. In vitro and in vivo spectrofluorometry of a water-soluble meta-(tetrahydroxyphenyl)chlorin (m-THPC) derivative. J Photochem Photobiol B Biol 1997; 39: 249-57.
23. Westermann P, Glanzmann T, Andrejevic S, et al. Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int J Cancer 1998; 76: 842-50.
24. Ris HB, Altermatt HJ, Inderbitzi R, et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: Initial clinical results. Br J Cancer 1991; 64: 1116-20.
25. Braichotte D, Savary JF, Glanzmann T, et al. Clinical pharmacokinetic studies of tetra(meta-hydroxyphenyl)-chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths. Int J Cancer 1995; 63: 198-204.
26. R̄, mTHPC). Lasers Med Sci 1996; 11: 267-72.
27. Vonarx-Coinsmann V, Foultier MT, Cempel N, et al. In vitro and in vivo photodynamic effects of a new photosensitizer: Tetra(m-hydroxyphenyl)chlorin. Lasers Med Sci 1994; 9: 173-81.
28. Gomer CJ, Ferrario A. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorine6 in a mouse tumor model. Cancer Res 1990; 50: 3985-90.
29. Ris HB, Altermatt HJ, Nachbur B, et al. Effect of drug-light interval on photodynamic therapy with m-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer 1993; 53: 141-6.
30. Morlet L, Vonarx-Coinsmann V, Lenz P, et al. Correlation between meta(tetrahydroxyphenyl)chlorin (m-THPC) biodistribution and photodynamic effects in mice. J Photochem Photobiol B Biol 1995; 28: 25-32.
31. Veenhuizen R, Oppelaar H, Ruevekamp M, et al. Does tumour uptake of foscan determine PDT efficacy. Int J Cancer 1997; 73: 236-9.